Discussion on the utilization of a newly developed and validated LC-MS/MS method for the simultaneous quantification of plasma levels of ivacaftor, tezacaftor, and elexacaftor in pediatric cystic fibrosis patients, focusing on its applications in therapeutic drug monitoring and pharmacokinetic studies.